EP 3197490 B1 20230621 - METHODS AND COMPOSITIONS FOR INTRA-NASAL IMMUNIZATION WITH RECOMBINANT MVA ENCODING FLAGELLIN
Title (en)
METHODS AND COMPOSITIONS FOR INTRA-NASAL IMMUNIZATION WITH RECOMBINANT MVA ENCODING FLAGELLIN
Title (de)
VERFAHREN UND ZUSAMMENSETZUNGEN ZUR INTRANASALEN IMMUNISIERUNG MIT REKOMBINANTEM, FLAGELLIN CODIERENDEM MVA
Title (fr)
PROCÉDÉS ET COMPOSITIONS POUR L'IMMUNISATION PAR VOIE INTRA-NASALE MVA DE RECOMBINAISON CODANT LA FLAGELLINE
Publication
Application
Priority
- EP 14186588 A 20140926
- EP 2015072076 W 20150925
Abstract (en)
[origin: WO2016046357A1] Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a flagellin, and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increased T-cell and antibody mediated immune responses specific for the heterologous disease-associated antigen when administered to a subject, e.g. a human subject, and related methods and uses.
IPC 8 full level
A61K 39/39 (2006.01); A61K 39/00 (2006.01); C07K 14/255 (2006.01)
CPC (source: EP US)
A61K 39/285 (2013.01 - US); A61K 39/295 (2013.01 - US); A61K 39/39 (2013.01 - EP US); A61P 31/20 (2018.01 - EP); A61P 37/04 (2018.01 - EP); C07K 14/255 (2013.01 - EP US); C12N 7/045 (2013.01 - US); A61K 2039/53 (2013.01 - US); A61K 2039/55516 (2013.01 - US); A61K 2039/55544 (2013.01 - US); A61K 2039/55594 (2013.01 - US); A61K 2039/57 (2013.01 - EP US); A61K 2039/572 (2013.01 - EP US); A61K 2039/58 (2013.01 - US); A61K 2039/6031 (2013.01 - EP US); A61K 2039/6068 (2013.01 - EP US); A61K 2039/64 (2013.01 - US); C12N 2710/24143 (2013.01 - EP US); C12N 2796/00 (2022.02 - US); Y02A 50/30 (2018.01 - EP)
Citation (examination)
- IOANNA SKOUNTZOU ET AL: "Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine", VACCINE, vol. 28, no. 24, 1 May 2010 (2010-05-01), pages 4103 - 4112, XP055173315, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2009.07.058
- HENNING LAUTERBACH ET AL: "Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity", FRONTIERS IN IMMUNOLOGY, vol. 4, 1 January 2013 (2013-01-01), XP055173263, ISSN: 1664-3224, DOI: 10.3389/fimmu.2013.00251
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2016046357 A1 20160331; AU 2015323736 A1 20170316; AU 2015323736 B2 20200910; CA 2960087 A1 20160331; CA 2960087 C 20240227; EP 3197490 A1 20170802; EP 3197490 B1 20230621; EP 3197490 C0 20230621; JP 2017530114 A 20171012; JP 2020183430 A 20201112; JP 7252180 B2 20230404; NZ 729519 A 20240223; US 10512684 B2 20191224; US 2017290909 A1 20171012
DOCDB simple family (application)
EP 2015072076 W 20150925; AU 2015323736 A 20150925; CA 2960087 A 20150925; EP 15766889 A 20150925; JP 2017513550 A 20150925; JP 2020124473 A 20200721; NZ 72951915 A 20150925; US 201515512820 A 20150925